First Patient Dosed in Phase 2 Stroke Trial of ARG-007
Filed with ASX · · 3 pages · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- FDA Grants Rare Pediatric Disease Designation For HIE
- Phase 2 Manufacturing Completed & Trial Update
- Appointment of Non-Executive Chair
- FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
- Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
Later from Argenica Therapeutics
- Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
- Argenica Successfully Completes $12.0m Placement
- DSMB Confirms Safety of First Patients Dosed
- ARG-007 Reduces Effects of TBI in Preclinical Study
- Appendix 4E & Annual Report to 30 June 2024
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics